YAP1 and Hyperbilirubinemia: Notably, the inhibition of both S‐phase and M‐phase progression prior to sHx induces full SFSS symptoms (steatosis, hypoalbuminemia, hyperbilirubinemia, increased mortality) akin to eHx.3 In contrast, sHx in YAP1‐deficient mice caused only mild SFSS (normal bilirubin, mild steatosis, slightly reduced mortality), again entirely consistent with a defect limited to the S‐phase.